ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

摘要:

As research into the pathogenesis of cancer becomes more sophisticated, a greater number of pathways and receptors become available for examination as potential therapeutic targets. Three such novel targets were described at the 25th Jubilee Conference of the New Zealand Society for Oncology [Auckland, New Zealand; February 1996]. They includep16gene mutations in hereditary melanoma, epidermal growth factor (EGF) receptors and the nuclear enzyme poly(ADP-ribose)polymerase (PARP).

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

摘要:

Tirapazamine is a new bioreductive agent that has exhibited cytotoxic activity against advanced tumours. Current studies are investigating how this agent can be used to its maximum potential. A combination of cisplatin and tirapazamine appears to be effective in chemotherapy-naive non-small cell lung cancer (NSCLC), leading to a greater response rate than that associated with cisplatin monotherapy. However, the combination has shown little promise in platinum-resistant tumours in phase II trials to date. Data from these studies were presented at the 9th National Cancer Institute (NCI) - European Organisation for the Research and Treatment of Cancer (EORTC) joint symposium [Amsterdam, The Netherlands; March 1996].

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS